Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank80
5Y CAGR+18.0%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+18.0%/yr
Long-term compound
Percentile
P80
Within normal range
vs 5Y Ago
2.3x
Strong expansion
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 43.49% |
| Q3 2025 | 28.72% |
| Q2 2025 | -2.96% |
| Q1 2025 | -44.99% |
| Q4 2024 | 34.81% |
| Q3 2024 | 9.03% |
| Q2 2024 | -8.72% |
| Q1 2024 | 32.12% |
| Q4 2023 | 17.85% |
| Q3 2023 | -28.37% |
| Q2 2023 | 57.73% |
| Q1 2023 | 3.43% |
| Q4 2022 | -11.76% |
| Q3 2022 | 21.27% |
| Q2 2022 | -34.27% |
| Q1 2022 | -25.43% |
| Q4 2021 | 45.43% |
| Q3 2021 | -19.83% |
| Q2 2021 | -17.13% |
| Q1 2021 | -24.08% |
| Q4 2020 | 19.03% |
| Q3 2020 | 40.74% |
| Q2 2020 | 6.81% |
| Q1 2020 | -8.67% |
| Q4 2019 | 3.96% |
| Q3 2019 | -28.64% |
| Q2 2019 | -47.94% |
| Q1 2019 | 64.04% |
| Q4 2018 | 74.98% |
| Q3 2018 | 20.02% |
| Q2 2018 | 36.18% |
| Q1 2018 | -57.80% |
| Q4 2017 | 113.67% |
| Q3 2017 | 51.08% |
| Q2 2017 | 194.82% |
| Q1 2017 | 0.00% |